Noven announced that the Food and Drug Administration (FDA) has approved a new indication with a new dose of Minivelle (estradiol transdermal system) for the prevention of postmenopausal osteoporosis.
The new 0.025mg/day patch is the smallest estrogen therapy patch measuring at 1.65 square cm, about one-third the size of Minivelle 0.0375mg/day.
Minivelle was initially approved in October 2012 for the treatment of moderate to severe vasomotor symptoms due to menopause. It is already available in 0.0375mg/day, 0.05mg/day, 0.075mg/day, and 0.1mg/day strengths for this indication.
The new Minivelle 0.025mg/day patch is expected to launch in January 2015.
For more information call (800) 455-8070 or visit Minivelle.com.